Why Preimplantation Genetic Testing has been a bust

Posted by Mrudula Anil Karmarkar on June 4th, 2021

The global preimplantation genetic testing market is expected to reach USD 107.3 million by 2024, at a CAGR of 6.2% over the forecast period, according to a new report by Grand View Research, Inc. It is primarily driven by a rising awareness among couples to undergo diagnostic and screening tests to minimize genetic diseases and aneuploidy in fetus. The ability of preimplantation genetic testing to detect genetic disorders and rare diseases, such as fibrodysplasia ossificans progressive, is anticipated to propel the growth.

High adoption of In Vitro Fertilization (IVF) technique consequently upsurges the utilization of Preimplantation Genetic Diagnosis (PGD). These techniques are advantageous in a way that they allow the development of a healthy fetus and prevent the risk of selective pregnancy termination. Hence, PGT acts as an addendum to assisted reproductive technology.

A substantial number of patients with infertility and impaired fecundity are recommended to embrace IVF therapy in combination with PGT procedures, which in turn is expected to stimulate the growth. In addition, public and private authorities are promoting reproductive health by undertaking initiatives is also anticipated to drive the Preimplantation Genetic Testing (PGT) (PGS/PGD) market.

Rising incidence single gene,mitochondrial, and other gene-related disorders, are attributed to increasing demand for preimplantation diagnosis and screening processes. As per the estimates made by the Florida Department of Health, about one in every 28 babies is diagnosed with a birth defect in Florida each year. Preimplantation Genetic Diagnosis (PGD) is implemented prior to IVF workflow for successful pregnancy. PGD is applicable in IVF cycles of women who faced several miscarriages or had last pregnancy with a chromosome abnormality. PGD can benefit the couples who are at risk of hereditary disorders, positively influencing the market.

The concept of aneuploidy screening during PGD has enhanced the IVF procedures. The introduction of aneuploidy testing in IVF centers identifies abnormal embryos; resulting in successful pregnancy rates. In August 2018, a study of Fertility and Sterility analyzed the successful IVF pregnancy outcomes by using Natera’s Spectrum PGT for aneuploidy (PGT-A).

Further key findings from the report suggest:

• Availability of a significant number of services related to early diagnosis of specific gene mutation in embryo marked the dominant position of PGD in 2018
• Preimplantation Genetic Screening (PGS) seems to be reasonable intervention to enhance efficiency of selecting chromosomally normal embryo during IVF cycles. It is increasingly being applied for embryo screening due to ever-expanding IVF, which is projected to create lucrative growth opportunities in near future
• Advancements in detection of chromosomal anomalies by executing non-invasive prenatal testing results in a maximum share of this segment in 2018
• Expanding utilization rate of FISH probe sets and benefits associated with the detection of a single-gene disorder is expected to fuel the growth of X-linked diseases segment
• Implementation of PGT in embryo HLA typing for stem cell therapy is expected to impose segment growth. This is further attributed to the advantages pertaining to PGS testing for identification of HLA compatible embryos during stem cell therapy
• Europe accounts for largest revenue share in 2018 owing to increased usage of PGD and PGS for the delivery of genetically healthy offspring during IVF procedures
• Asia Pacific market is observed to reveal the fastest CAGR due to the rise in medical tourism and the continuous development of IVF and PGD clinics in Asian countries

Moreover, subsequent innovations in genetic diagnosis such as an introducing PGT monogenic disease diagnosis (PGT-M), stimulates the industrial growth. PGT-M focus on identification of Mendelian genetic disorder in embryo for addressing challenges of prenatal diagnosis as it precludes the chances of elective termination of pregnancy.

Number of supportive initiatives adopted by the government authorities to promote reproductive health, also drive the market. For instance, in June 2017, Switzerland government approved the pre-implantation genetic diagnosis of an in-vitro embryo. Such initiatives focus on detecting and minimizing genetic anomalies affecting embryos before implantation.

Ethical acceptability and legal regulations by public entities impede the adoption rate of PGT services thereby hampering the growth. However, awareness regarding health of fetus among couples and expanding applications of PGD and Preimplantation Genetic Screening (PGS) collectively create opportunities for market progression.

Have a Query? Ask Our Expert:

https://www.grandviewresearch.com/inquiry/3258/ibb

Some of the key players are Illumina Inc.; Thermo Fisher Scientific, Inc.; Natera, Inc.; Bioarray S.L.; Good Start Genetics, Inc.; Laboratory Corporation of America Holdings; California Pacific Medical Center; Quest Diagnostics Incorporated; Reproductive Health Science Ltd.; CooperSurgical, Inc.; Genea Limited; IGENOMIX; Reproductive Genetic Innovations, LLC; F. Hoffmann-La Roche AG; and CombiMatrix.

Continuous developments incorporated by key participants in genetic diagnosis for successful implementation of PGT as well as screening, expands their market share significantly. Key players adopt several strategic initiatives such as geographical expansions, collaborative developments, and new product developments.

Grand View Research has segmented the global Preimplantation Genetic Testing (PGT) (PGS/PGD) market on the basis of PGD/PGS, type, application:

Preimplantation Genetic Testing (PGT) PGD/PGS Outlook (Revenue, USD Million, 2014 - 2024)

• Preimplantation Genetic Diagnosis (PGD)
• Preimplantation Genetic Screening (PGS)

Preimplantation Genetic Testing (PGT) (PGS/PGD) Type Outlook (Revenue, USD Million, 2014 - 2024)

• Chromosomal Abnormalities
• X-linked Diseases
• Embryo Testing
• Fresh Embryo (Own Eggs)
• Frozen Embryo (Own Eggs)
• Fresh Embryo (Donor Eggs)
• Frozen Embryo (Donor Eggs)
• Aneuploidy Screening
• HLA Typing
• Other PGT Types

Preimplantation Genetic Testing (PGT) (PGS/PGD) Application Outlook (Revenue, USD Million, 2014 - 2024)

• Embryo HLA typing for stem cell therapy
• IVF Prognosis
• Late Onset Genetic Disorders
• Inherited Genetic Disease
• Others

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information:www.grandviewresearch.com